[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
February 6, 2013

β-Blocker Use for Patients With or at Risk for Coronary Artery Disease

Author Affiliations

Letters Section Editor: Jody W. Zylke, MD, Senior Editor.

Author Affiliations: INSERM et Université Pierre et Marie Curie, Paris, France (Dr Costagliola; dominique.costagliola@ccde.chups.jussieu.fr); and Departments of Epidemiology and Biostatistics, Harvard School of Public Health, Boston, Massachusetts (Dr Hernán).

JAMA. 2013;309(5):438. doi:10.1001/jama.2012.128862

To the Editor: Observational studies are increasingly being used for comparative effectiveness research. To be relevant for clinical practice, observational studies need to mimic RCTs as closely as possible. The study by Dr Bangalore and colleagues1 illustrates several ways in which an observational study may unnecessarily differ from an RCT. The authors wanted to estimate the effect of β-blocker use on cardiovascular disease among patients with prior MI, those with prior CAD but without MI, and those with CAD risk factors.